|
|
||||||||
1 Department of Molecular Biosciences, Swedish University of Agricultural Sciences, The Biomedical Centre, S-751 23 Uppsala, Sweden
2 Department of Medical Biochemistry and Biophysics and
3 Department of Cell and Molecular Biology, Medical Nobel Institute, Karolinska Institutet, S-171 77 Stockholm, Sweden
(RECEIVED September 17, 2003; FINAL REVISION December 2, 2003; ACCEPTED January 20, 2004)
-helical to
-sheet conformation and form amyloid fibrils, including the amyloid
-peptide (A
) and the prion protein, contain a discordant
-helix that is composed of residues that strongly favor
-strand formation. In their native states, 37 of 38 discordant helices are now found to interact with other protein segments or with lipid membranes, but A
apparently lacks such interactions. The helical propensity of the A
discordant region (K16LVFFAED23) is increased by introducing V18A/F19A/F20A replacements, and this is associated with reduced fibril formation. Addition of the tripeptide KAD or phospho-L-serine likewise increases the
-helical content of A
(1228) and reduces aggregation and fibril formation of A
(140), A
(1228), A
(1224), and A
(1423). In contrast, tripeptides with all-neutral, all-acidic or all-basic side chains, as well as phosphoethanolamine, phosphocholine, and phosphoglycerol have no significant effects on A
secondary structure or fibril formation. These data suggest that in free A
, the discordant
-helix lacks stabilizing interactions (likely as a consequence of proteolytic removal from a membrane-associated precursor protein) and that stabilization of this helix can reduce fibril formation.
Abbreviations: A
, amyloid
-peptide AD, Alzheimers disease APP, amyloid precursor protein ASA, accessible surface area CD, circular dichroism PrP, prion protein TFE, trifluoroethanol ThT, thioflavin T
Keywords:
-helix; protein structure; protein aggregation; conformational disease
Reprint requests to: Jan Johansson, Department of Molecular Biosciences, Swedish University of Agricultural Sciences, The Biomedical Centre, Box 575, S-751 23 Uppsala, Sweden; e-mail: jan.johansson{at}vmk.slu.se; fax: 46-18-550762.
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.03442404.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Bibl, B. Mollenhauer, H. Esselmann, P. Lewczuk, H.-W. Klafki, K. Sparbier, A. Smirnov, L. Cepek, C. Trenkwalder, E. Ruther, et al. CSF amyloid-{beta}-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain, May 1, 2006; 129(5): 1177 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.R. Chen, H.B. Huang, C.L. Chyan, M.S. Shiao, T.H. Lin, and Y.C. Chen The Effect of A{beta} Conformation on the Metal Affinity and Aggregation Mechanism Studied by Circular Dichroism Spectroscopy. J. Biochem., April 1, 2006; 139(4): 733 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Kim and M. H. Hecht Sequence Determinants of Enhanced Amyloidogenicity of Alzheimer A{beta}42 Peptide Relative to A{beta}40 J. Biol. Chem., October 14, 2005; 280(41): 35069 - 35076. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |